The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CAR-T Meeting 2026 | The role of post-transplant DLI to eradicate MRD in leukemia
In this video, Jürgen Kuball, MD, PhD, Utrecht University, Utrecht, Netherlands, briefly discusses the role of post-transplant donor lymphocyte infusion (DLI) in eradicating measurable residual disease (MRD) in patients with leukemia. Dr Kuball highlights the need for effective data collection to determine the optimal timing of DLI to avoid over- or under-treatment. This interview took place at the EBMT-EHA 8th European CAR T-cell Meeting, held in Palma de Mallorca, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
One of the major challenges in allotransplant, in particular for leukemia, is that you have still minimal residual disease, meaning that you have some leukemia cells you cannot detect. And one way to attack this is with a donor lymphocyte infusion. And nowadays, as also a lot of other drugs are entering the market, which can be used also post-transplant like TKIs, it’s a new challenge, how do we monitor MRD and at which moment do we give the DLI? This will require in the future also a very good collection of data because everybody’s doing it a bit differently and should be carefully monitored because you should not overdo it, but you should also not forget it...
One of the major challenges in allotransplant, in particular for leukemia, is that you have still minimal residual disease, meaning that you have some leukemia cells you cannot detect. And one way to attack this is with a donor lymphocyte infusion. And nowadays, as also a lot of other drugs are entering the market, which can be used also post-transplant like TKIs, it’s a new challenge, how do we monitor MRD and at which moment do we give the DLI? This will require in the future also a very good collection of data because everybody’s doing it a bit differently and should be carefully monitored because you should not overdo it, but you should also not forget it. And finding this balance, please read the ASH educational we wrote.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Cofounder and shareholder: Gadeta Founders B.V.; Inventor on patents related to γδTCR/ligand and genetic engineering; Research funding: Novartis, Miltenyi Biotech, and Gadeta.
